中恒集团：控股孙公司纳米炭铁混悬注射液药物临床试验获批

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection," to conduct clinical trials in solid tumor patients [1] Group 1 - The drug is set to be tested in conjunction with standard radiotherapy [1] - The approval marks a significant step in the development of new cancer treatments by the company [1]